Clinical trials: Genotype
Non-Small Cell Lung Cancer
Liquid Biopsy Genotyping Using Oncomine Precision Assay GX in Advanced NSCLC
This interventional clinical study evaluates the clinical utility and feasibility of the Oncomine Precision Assay GX method for genotyping circulating tumor DNA (ctDNA) in patients with advanced non-small cell lung cancer…
- Trial name
- Liquid biopsy (NCT07432308)
- Testing
- Oncomine Precision Assay GX ctDNA Testing
- Where
- Slovenia
- Volunteers
- 22 people
- Sponsor
- Institute of Oncology Ljubljana
Chronic Hepatitis C
Simeprevir in Combination With Sofosbuvir in Treatment-Naïve or -Experienced Adults With Chronic Genotype 4 Hepatitis C Virus Infection
This study will look at the safety and efficacy of 8 week and 12 week treatment with Sofosbuvir and Simeprevir in treatment-naïve and treatment-experienced patients with chronic hepatitis C genotype 4.
- Trial name
- NCT02253550
- Testing
- Simeprevir, Sofosbuvir
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Peter J. Ruane, M.D.
Leprosy
Improved Understanding of Ongoing Transmission of Leprosy in the Hyperendemic Comoros (ComLep)
Despite decades of a solid leprosy control program, including active case finding and follow-up on therapeutic outcome, the Comoros islands of Anjouan and Moheli continue to be hyperendemic for leprosy, with leprosy case…
- Trial name
- ComLep (NCT03526718)
- Where
- Comoros
- Volunteers
- 889 people
- Sponsor
- Institute of Tropical Medicine, Belgium
Chronic Renal Failure
Effects of Cyclosporine A on Pancreatic Insulin Secretion
Our primary aim is to investigate if cyclosporine A reduces insulin secretion.
- Trial name
- NCT00139035
- Testing
- cyclosporine A
- Where
- Norway
- Volunteers
- 16 people
- Sponsor
- University of Oslo School of Pharmacy
Hepatitis C Virus Infection
Ombitasvir /Paritaprevir/Ritonavir Plus Ribavirin on HCV GT4
The objective of the investigators was to delineate the efficacy and safety of Ombitasvir, paritaprevir with ritonavir (OBV/PTV/r) plus ribavirin (RBV) on chronic HCV GT4 Egyptian naïve patients
- Trial name
- NCT04378608
- Testing
- OBV/PTV/r) ± ribavirin (RBV)
- Volunteers
- 100 people
- Sponsor
- Beni-Suef University
Hepatitis C, Chronic Pain
Efficacy and Safety of Alisporivir Alone or Combined With RBV or PEG in Chronic Hepatitis C Genotype 2 and 3 Treatment-naïve Participants
The study is to investigate whether alisporivir (ALV; DEB025) alone or in combination with either ribavirin (RBV) or peginterferon alfa-2a (PEG) is more efficient compared to standard of care (PEG+RBV) in treatment-naïve…
- Trial name
- NCT01215643
- Testing
- Alisporivir, Peginterferon alfa-2a, Ribavirin
- Where
- 73 sites in United States, Australia and 12 more
- Volunteers
- 340 people
- Sponsor
- Debiopharm International SA
Chronic Hepatitis C
A Single Ascending Dose Study of BMS-650032 in HCV Infected Subjects
The primary purpose of this study is to evaluate the safety profile and tolerability of single oral doses of BMS-650032 in subjects with chronic hepatitis C infection
- Trial name
- NCT00559247
- Where
- 5 sites in United States
- Volunteers
- 24 people
- Sponsor
- Bristol-Myers Squibb
Hepatitis C, Chronic
First in Human Study of ALS-002158; Single Dose, Food Effect in Healthy Volunteers; Multiple Doses in Chronic Hepatitis C Genotype 1
This randomized, double-blind, placebo-controlled, 3-part study will assess the safety, tolerability, and pharmacokinetics of orally administered ALS-002158 in healthy volunteers (HV) and subjects with chronic hepatitis C (CHC)…
- Trial name
- NCT01554085
- Testing
- ALS-002158
- Where
- 5 sites in Australia, New Zealand
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- Alios Biopharma Inc.
Metastatic Pancreatic Cancer
Metronomic Capecitabine, Oxaliplatin and UGT1A1 Genotype-directed Irinotecan in Metastatic Pancreatic Cancer Patients
This is a single-centre, non-randomized, open label phase II trial to be conducted at the National Cancer Centre, Singapore (NCCS). Patients diagnosed with metastatic PDAC will be eligible to enrol.
- Trial name
- NCT05929885
- Testing
- Low Dose OXIRI (LD-OXIRI)
- Where
- Singapore
- Volunteers
- 50 people
- Sponsor
- National Cancer Centre, Singapore
Hepatitis C, Chronic
Safety and Efficacy of Boceprevir in Previously Untreated Subjects With Chronic Hepatitis C Genotype 1 (Study P05216AM2) (COMPLETED)
This study involves treatment with boceprevir or placebo in combination with PegIntron (PEG) + Ribavirin (RBV) (weight-based dosing [WBD]) in previously untreated adult participants with chronic hepatitis C (CHC) genotype 1.
- Trial name
- SPRINT-2 (NCT00705432)
- Testing
- Peginterferon alfa-2b (PEG), Ribavirin (RBV), Boceprevir
- Volunteers
- 1,472 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C Virus
Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of Simeprevir, Daclatasvir and Sofosbuvir in Treatment-naive Participants With Chronic Hepatitis C Virus Genotype 1 Infection
The purpose of this study is to evaluate the efficacy of 6 or 8 weeks of treatment regimen containing simeprevir (SMV), daclatasvir (DCV) and sofosbuvir (SOF) in treatment-naive (not having received treatment with any approved or…
- Trial name
- ACCORDION-1 (NCT02349048)
- Testing
- Simeprevir 150 mg, Daclatasvir 60 mg, Sofosbuvir 400 mg
- Where
- 8 sites in United States, Canada
- Volunteers
- 68 people
- Sponsor
- Janssen Research & Development, LLC
Invasive GAS Infection
Invasive Group A Streptococcus (GAS) Infection in Children: Bacterial Virulence Factors and Detection of Host Immunological and/or Genetic Factors of Predisposition to Infections
The main objective of the study is to characterize the virulence factors of SGA and identify immunological and / or genetic factors predisposing to infections in children hospitalized with invasive GAS infection.
- Trial name
- StreptoPedia (NCT02010294)
- Testing
- DNA samples, GAS strains
- Where
- France
- Volunteers
- 223 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
DFNA9
Systematic Review of Phenotypical Characteristics of P51S COCH Mutation
Gene mutations account for more than 60% of congenital sensorineural hearing loss (SNHL) in Western Countries. Hereditary SNHL does not necessarily start at birth, however, as many causative gene mutations only begin to express…
- Trial name
- NCT03707756
- Sponsor
- Jessa Hospital
Hepatitis C
Efficacy and Safety of Combination Grazoprevir (MK-5172) + Elbasvir (MK-8742) + Ribavirin (RBV) in Genotype 2 Hepatitis C Infection (MK-5172-047)
This is a multi-site, open-label trial evaluating the safety and efficacy of 100 mg of grazoprevir (MK-5172) used in combination with or without 50 mg of elbasvir (MK-8742) and/or ribavirin (RBV) in treating non-cirrhotic…
- Trial name
- NCT01932762
- Testing
- Grazoprevir, Elbasvir, Ribavirin
- Volunteers
- 98 people
- Sponsor
- Merck Sharp & Dohme LLC
Smoking Cessation
Evaluation of a Tailored Smoking Cessation Treatment Algorithm Based on Initial Treatment Response and Genotype
Nicotine replacement therapy (NRT) is a well-tolerated and efficacious smoking cessation treatment, and yet many smokers fail to quit using NRT.
- Trial name
- ConNic3 (NCT00894166)
- Testing
- Nicotine Patches, Nicotine patches, then bupropion & nicotine patches (Pre-Quit), Nicotine patches, then varenicline (Pre-Quit)
- Where
- United States
- Volunteers
- 606 people
- Sponsor
- Duke University
Pneumocystis Pneumonia
Pneumocystis Jirovecii Genotyping
We share our lives with microorganisms, and these generally do not pose a problem if an individual is healthy with a normal immune system.
- Trial name
- NCT06442345
- Volunteers
- 70 people
- Sponsor
- Nottingham University Hospitals NHS Trust
Viral Hepatitis C
SVR12 in Genotype 3 HCV (F0-F2) Treated With RDV + SOF
This study will follow a group of people with chronic hepatitis C infection of genotype 3 who have mild to moderate liver fibrosis (stages F0-F2, measured by a liver stiffness test).
- Trial name
- NCT07316842
- Where
- Russia
- Volunteers
- 30 people
- Sponsor
- Center of target therapy
HIV
Open Label Trial of PEG-IFN, RBV & TVR vs. PEG-IFN & RBV Alone in Tx of HCV-1 in HIV-1 Co-infected Patients (CHAT)
The purpose of the study is to explore the treatment of patients with acute hepatitis C infection (infection acquired within the last 6 months) who are also infected with human immunodeficiency virus (HIV).
- Trial name
- CHAT (NCT02006745)
- Testing
- Ribavirin, Telaprevir
- Where
- United Kingdom
- Volunteers
- 20 people
- Sponsor
- St Stephens Aids Trust
Chronic Hepatitis C Infection, Fatty Liver
Assessing the Efficacy and Safety of Rosiglitazone Added to Standard Therapy for Hepatitis C Genotype 1 With Fatty Liver
To study the effectiveness and safety of adding Rosiglitazone, an insulin sensitizing agent to people with chronic hepatitis C infection genotype 1 with fatty liver disease, who are being treated with standard therapy.
- Trial name
- NCT00274495
- Testing
- Rosiglitazone and Pegasys/Ribavirin
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Beth Israel Medical Center
Hepatitis C
Safety and PK Study of NOV-205 to Treat Chronic HCV Who Fail Standard Therapy
The purpose of this research trial is to find out whether NOV-205 is well tolerated compared to placebo (salt water) in people with hepatitis C.
- Trial name
- NCT00372983
- Testing
- NOV-205
- Volunteers
- 30 people
- Sponsor
- Cellectar Biosciences, Inc.